SLGT2i for Neuroprotection in Patients With Acute Ischemic Stroke

"Any of the following SGLT2 inhibitors (SGLT2i) can be selected for treatment:~Dapagliflozin 10 mg once daily (QD) or Empagliflozin 10 mg once daily (QD) If the patient has concurrent diabetes, the use of other antidiabetic drugs is not restricted.~The treatment should last for at least 14 days."

According to the guideline-recommended standard treatment, if the patient has diabetes, there is no restriction on the use of other antidiabetic drugs (except SGLT-2 inhibitors).